Unknown

Dataset Information

0

Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations.

ABSTRACT:

SUBMITTER: Wong A 

PROVIDER: S-EPMC6830961 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations.

Wong Alexander A   Goldstein Deborah D   Mallolas Josep J   DeJesus Edwin E   Johnson Margaret M   Molina Jean-Michel JM   Pozniak Anton A   Rodgers Anthony A   Teal Valerie V   Hepler Deborah D   Kumar Sushma S   Sklar Peter P   Hanna George J GJ   Hwang Carey C   Badshah Cyrus C   Teppler Hedy H  

Journal of acquired immune deficiency syndromes (1999) 20191201 4

Similar Datasets

Unknown Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial.
| S-EPMC6905402 | biostudies-literature
Unknown Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate for Nonoccupational HIV-1 Postexposure Prophylaxis: A Prospective Open-Label Trial (DORAVIPEP).
| S-EPMC10394723 | biostudies-literature
Unknown Lamivudine/Tenofovir Disoproxil Fumarate is an Appropriate PrEP Regimen.
| S-EPMC7710557 | biostudies-literature
Unknown Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial.
| S-EPMC6355823 | biostudies-literature
Unknown Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1.
| S-EPMC7577165 | biostudies-literature
Unknown Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014.
| S-EPMC9839475 | biostudies-literature
Unknown Efficacy, Safety, and Tolerability of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Results Through Week 96 from IMPAACT 2014.
| S-EPMC11494224 | biostudies-literature
Unknown Switch to Fixed Dose of Doravirine, Lamivudine, Tenofovir Disoproxil Fumarate Versus Bictegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate in Virologically Suppressed Adults on Efavirenz-Based Regimens: 48-Week Results of a Real-world, Prospective, Observational Cohort Study.
| S-EPMC12817991 | biostudies-literature
Unknown Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients.
| S-EPMC5766122 | biostudies-literature
Unknown Comparative pharmacokinetics between tenofovir disoproxil phosphate and tenofovir disoproxil fumarate in healthy subjects.
| S-EPMC8020360 | biostudies-literature